PSYENCE BIOMEDICAL LTD
COM NEW · CUSIP 74449F209
0
institutional holders
-1 vs Q2 2025
—reported value*
0 new
0 added
0 reduced
1 sold out
net sold ≈ $462.0k (-275.0k shares)
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable.
Trends to Q3 2025
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q4 2024 | 12 |
| Q1 2025 | 9 |
| Q2 2025 | 1 |
| Q3 2025 | 0 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Bought or addedCut or sold out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q1 2025 | 8 | 7 |
| Q2 2025 | 1 | 9 |
| Q3 2025 | 0 | 1 |
Biggest buyers
| None |
Biggest sellers
| Parallel Advisors, LLC | Sold out | -275.0k |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
Psyence Group Inc.
13D · may seek influence
filed 2025-03-25
Stated purposeThe information set forth in Item 3 is hereby incorporated by reference in its entirety. Except for the foregoing, the Reporting Person has no plans or proposals which relate to, or could result in, any of the matters referred to in paragraphs (a) and (c) through (j) of Item 4 of Schedule 13D. Full filing |
15.0% |
Holders, Q3 2025
| Manager | Shares | Change |
|---|